Floatz logo

Autologous Nk Cells

NSCLC Stage IIIA/B

Technical University of MunichCell therapyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

1206 Active assets in the NSCLC Stage IIIA/B cohort.

Asset / SponsorPhaseRating
Necitumumab
Jonsson Comprehensive Cancer Center
Phase 3BBB
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BBB
Glumetinib
Shanghai JMT-Bio Inc.
Phase 3BBB
d-0316
Betta Pharmaceuticals Co., Ltd.
Phase 2/3BBB
Onartuzumab
Hoffmann-La Roche
Phase 3BBB

View all 50 →

Same molecule, other indications

Autologous Nk Cells is also rated in:

Persistent/Recurrent Minimal Residual Disease (MRD)Dormant
CC
Indicative ·
47 / 100
View asset →
hepatocellular carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
squamous cell lung carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →